Surgical Device Value Analysis Committee Commercial Launch Brief

Role: Senior Vice President of MedTech Value Access & Commercial Operations.

Context

• Device Brand & Portfolio: {{device_brand}}
• Target Surgical Specialty: {{surgical_procedure_type}}
• Target Hospital Tier / IDN: {{hospital_procurement_target}}
• Clinical Efficacy & Operating Room (OR) Impact: {{clinical_efficacy_metric}}
• Per-Procedure Cost Delta vs Standard of Care: {{per_procedure_cost_delta}}
• Risk-Sharing / Value-Based Contracting Model: {{risk_share_mechanism}}

Task

Draft a rigorous Value Analysis Committee (VAC) commercial launch brief for {{device_brand}} that equips territory managers to overcome hospital procurement gates, secure surgeon advocacy, and prove immediate perioperative value across {{hospital_procurement_target}}.

Method

1. Translate {{clinical_efficacy_metric}} into quantifiable operating room efficiency metrics (e.g., reduced OR time, reduced revision rates, lower complication costs).
2. Construct the financial dossier justifying {{per_procedure_cost_delta}}, factoring in sterilization overhead, length of stay, and readmission penalties.
3. Map the dual-stakeholder engagement framework: navigating clinical champion (Surgeon) mobilization vs administrative gatekeeper (Materials Management/VAC) approvals.
4. Articulate the commercial implementation of {{risk_share_mechanism}} to de-risk hospital adoption during the initial trial period.
5. Formulate standard VAC dossier submission templates, including clinical evidence summaries, sterilization guidelines, and supply chain continuity guarantees.
6. Create competitive displacement battlecards targeting the incumbent standard of care within {{surgical_procedure_type}}.
7. Detail the territory field sales execution cadence, tracking surgeon shadowing, committee presentation scheduling, and supply chain onboarding.

Constraints

• MUST present a fully substantiated net-economic calculation accounting for {{per_procedure_cost_delta}} across a typical 100-procedure hospital cohort.
• MUST NOT rely solely on clinical preference; every clinical assertion must connect to an economic or operational outcome.
• Maintain strict compliance with Anti-Kickback Statute guidelines regarding device evaluation units and surgeon consulting.
• All operational metrics must reflect actual acute-care inpatient hospital constraints.

Output format

Provide the brief structured in five sequential modules:

1. VAC Executive Dossier & Business Case (max 300 words framing total value impact)
2. Dual-Track Stakeholder Matrix (Surgeon Champions vs VAC Procurement Committee)
3. 100-Procedure Economic Impact Model (table showing procedural costs, complications, and net hospital savings)
4. Risk-Share Contracting Playbook (operationalizing {{risk_share_mechanism}})
5. 90-Day Field Commercial Action Plan (divided into Discovery, Committee Review, and In-Service Training).

Self-review

• Verify that the 100-procedure financial model accurately incorporates {{per_procedure_cost_delta}}.
• Ensure the clinical benefits directly map to the operational metrics in {{clinical_efficacy_metric}}.
• Confirm that the contractual guardrails for {{risk_share_mechanism}} are legally and commercially viable.